Primary Sclerosing Cholangitis. Multiple Phenotypes, Multiple Approaches.

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a heterogeneous, idiopathic, inflammatory disorder frequently associated with inflammatory bowel diseases. PSC patients may be classified into several subphenotypes. Investigations of pediatric, nonwhite, and female PSC patients have revealed distinguishing features. The natural history of PSC is variable in progression with numerous possible clinical outcomes. PSC patients may suffer bacterial cholangitis, cholangiocarcinoma, or colorectal adenocarcinoma. Treatments focusing on bile acid therapy and immunosuppression have not proven beneficial. Interest in PSC and international collaboration has led to improved understanding of the heterogeneity and the genetic structure and introduced possible effective therapeutics.

Original languageEnglish (US)
Pages (from-to)67-77
Number of pages11
JournalClinics in Liver Disease
Volume20
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Sclerosing Cholangitis
Phenotype
Cholangitis
Cholangiocarcinoma
Genetic Structures
Bile Acids and Salts
Inflammatory Bowel Diseases
Immunosuppression
Adenocarcinoma
Therapeutics
Pediatrics

Keywords

  • Autoimmune hepatitis
  • Diagnosis
  • IgG4-related sclerosing cholangitis
  • Primary sclerosing cholangitis
  • Treatment

ASJC Scopus subject areas

  • Hepatology

Cite this

Primary Sclerosing Cholangitis. Multiple Phenotypes, Multiple Approaches. / Sarkar, Souvik; Bowlus, Christopher.

In: Clinics in Liver Disease, Vol. 20, No. 1, 01.02.2016, p. 67-77.

Research output: Contribution to journalArticle

@article{594b1a6b67554bacb87f71646ca3ef4e,
title = "Primary Sclerosing Cholangitis. Multiple Phenotypes, Multiple Approaches.",
abstract = "Primary sclerosing cholangitis (PSC) is a heterogeneous, idiopathic, inflammatory disorder frequently associated with inflammatory bowel diseases. PSC patients may be classified into several subphenotypes. Investigations of pediatric, nonwhite, and female PSC patients have revealed distinguishing features. The natural history of PSC is variable in progression with numerous possible clinical outcomes. PSC patients may suffer bacterial cholangitis, cholangiocarcinoma, or colorectal adenocarcinoma. Treatments focusing on bile acid therapy and immunosuppression have not proven beneficial. Interest in PSC and international collaboration has led to improved understanding of the heterogeneity and the genetic structure and introduced possible effective therapeutics.",
keywords = "Autoimmune hepatitis, Diagnosis, IgG4-related sclerosing cholangitis, Primary sclerosing cholangitis, Treatment",
author = "Souvik Sarkar and Christopher Bowlus",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.cld.2015.08.005",
language = "English (US)",
volume = "20",
pages = "67--77",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Primary Sclerosing Cholangitis. Multiple Phenotypes, Multiple Approaches.

AU - Sarkar, Souvik

AU - Bowlus, Christopher

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Primary sclerosing cholangitis (PSC) is a heterogeneous, idiopathic, inflammatory disorder frequently associated with inflammatory bowel diseases. PSC patients may be classified into several subphenotypes. Investigations of pediatric, nonwhite, and female PSC patients have revealed distinguishing features. The natural history of PSC is variable in progression with numerous possible clinical outcomes. PSC patients may suffer bacterial cholangitis, cholangiocarcinoma, or colorectal adenocarcinoma. Treatments focusing on bile acid therapy and immunosuppression have not proven beneficial. Interest in PSC and international collaboration has led to improved understanding of the heterogeneity and the genetic structure and introduced possible effective therapeutics.

AB - Primary sclerosing cholangitis (PSC) is a heterogeneous, idiopathic, inflammatory disorder frequently associated with inflammatory bowel diseases. PSC patients may be classified into several subphenotypes. Investigations of pediatric, nonwhite, and female PSC patients have revealed distinguishing features. The natural history of PSC is variable in progression with numerous possible clinical outcomes. PSC patients may suffer bacterial cholangitis, cholangiocarcinoma, or colorectal adenocarcinoma. Treatments focusing on bile acid therapy and immunosuppression have not proven beneficial. Interest in PSC and international collaboration has led to improved understanding of the heterogeneity and the genetic structure and introduced possible effective therapeutics.

KW - Autoimmune hepatitis

KW - Diagnosis

KW - IgG4-related sclerosing cholangitis

KW - Primary sclerosing cholangitis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84947763568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947763568&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2015.08.005

DO - 10.1016/j.cld.2015.08.005

M3 - Article

C2 - 26593291

AN - SCOPUS:84947763568

VL - 20

SP - 67

EP - 77

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 1

ER -